About Virtual European Migrants HIV & Ageing Conference London 17-18 July 2020
EATAN in partnership with Treatment Action Group (TAG) are organising the European Migrants HIV &Ageing conference due to take place in London June 2020. The conference will bring together a cross disciplinary team of experts, clinicians, policy makers, people living with HIV, African LGBTI community and other community members involved in HIV / Ageing activities.
Migrants from high-prevalence and other countries continue to be vulnerable to HIV. Despite a decline in the proportion of new reported cases among migrants originating from sub-Saharan Africa, migrants still represent a significant proportion of all newly diagnosed HIV cases reported in the EU/EEA and are a key population for prevention and control efforts in many EU/EEA countries. Dublin Declaration monitoring suggests that current HIV prevention efforts are inadequate for this population, with many EU/EEA countries reporting gaps in prevention programs for migrants.
The increase in newly diagnosed cases among migrants originating from countries without high-prevalence HIV highlights the need for EU/EEA country-specific data on migrant populations who are at risk. There is also growing evidence that some migrants, in particular migrants from high-prevalence countries and migrant MSM, are at risk of HIV acquisition after arrival in the EU/EEA. Improved monitoring, better understanding of risk factors and targeted prevention programs are needed to address this. Available data suggest that rates of HIV testing among migrants are low and there is also clear evidence that some migrant populations are more likely to be diagnosed later than other populations.
Specific measures are needed to increase early uptake of testing and reduce late diagnosis among those migrant populations most at risk. Such measures include addressing barriers to provision and uptake of HIV testing services and using innovative approaches to improve access to testing. Although almost all countries in the region provide ART for documented migrants, only half do so for undocumented migrants. In addition, undocumented migrants face a range of barriers that make it more difficult for them to access HIV prevention and testing services.
The use of antiretroviral therapy (ART) into HIV care has increased the life expectancy of people living with HIV among migrant communities in Europe. The longer life expectancy of people with HIV infection is changing the demographics of the HIV epidemic and currently, more than In comparison to similar HIV-negative populations, HIV-positive persons, even when on effective ART, experience an excess of morbidity and mortality.
Persons on ART rarely die from complications of AIDS, but instead have early onset of aging complications including neurocognitive decline, osteoporosis and fractures, impaired physical function, frailty, and falls. The high priority on understanding the interaction between age and HIV infection is illustrated by recent summary reports from the HIV and Aging Consensus Project in the Journal of the American Geriatrics Society and ongoing NIH Program Announcements in “Multidisciplinary Studies of HIV/AIDS and Aging”, in addition to strong voices in the community.
The multidisciplinary nature of HIV and aging requires joining expertise in many areas, including geriatrics, internal medicine, HIV, pharmacology, psychology, and numerous subspecialties. Indeed, the European migrant’s conference on HIV & Aging initiated by EATAN in partnership with is unique and much-needed platform for scientific exchange on the increasingly recognised difficulties encountered in the clinical care and design of research
Conference Main Objectives
- To increase awareness within European migrant patient community, researchers, healthcare providers and other key stakeholders of the unmet clinical and psychosocial needs of PLHIV/AIDS at different stages in their lives, and to identify advocacy priorities in the HIV and ageing.
- To empower Migrant PLHIV/AIDS aged 50+ to make informed decisions regarding their treatment.
- To have increased awareness within the patients’ community; researchers; healthcare providers , Pharmaceuticals and other key stakeholders.
- To have advocacy needs identified in order to better respond to the varied needs of Migrant PLHIV aged 50+ and for early detection and treatment of HIV and co-related infections.
- To be able to develop policy recommendations focused responses on prevention, testing and treatment for Migrants PLHIV aged over 50 including older age.
Treatment Action Group (TAG) is an independent, activist and community-based research and policy think tank fighting for better treatment, prevention, a vaccine, and a cure for HIV, tuberculosis, and hepatitis C virus. TAG works to ensure that all people with HIV, TB, or HCV receive lifesaving treatment, care, and information. We are science-based treatment activists working to expand and accelerate vital research and effective community engagement with research and policy institutions. TAG catalyses open collective action by all affected communities, scientists, and policy makers to end HIV, TB, and HCV.